Details for Patent: 12,648,930
✉ Email this page to a colleague
Which drugs does patent 12,648,930 protect, and when does it expire?
Patent 12,648,930 protects UPNEEQ and is included in one NDA.
This patent has twenty-nine patent family members in seventeen countries.
Drugs Protected by US Patent 12,648,930
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | 12,648,930 | ⤷ Start Trial | METHOD OF TREATING BLEPHAROPTOSIS | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,648,930
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020268329 | ⤷ Start Trial | |||
| Brazil | 112021022404 | ⤷ Start Trial | |||
| Canada | 3139443 | ⤷ Start Trial | |||
| Chile | 2021002918 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
